Novavax (NVV1) Stock Forecast & Price Target

Compare

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVV1 Analyst Ratings

Hold

3 Buy

1 Hold

2 Sell

Based on 6 analysts giving stock ratings to

Novavax

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVV1 Stock 12 Month Forecast

Average Price Target

€9.72

▲(24.98% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Novavax in the last 3 months. The average price target is €9.72 with a high forecast of €16.06 and a low forecast of €5.07. The average price target represents a 24.98% change from the last price of €7.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","17":"€17","7.25":"€7.25","10.5":"€10.5","13.75":"€13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.06447435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.723234475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€9.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.0729919,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.07</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.25,10.5,13.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.405,8.071113411538462,8.737226823076924,9.403340234615385,10.069453646153846,10.735567057692307,11.401680469230769,12.06779388076923,12.733907292307691,13.400020703846153,14.066134115384614,14.732247526923077,15.398360938461538,{"y":16.06447435,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.405,7.583325728846154,7.761651457692308,7.939977186538462,8.118302915384616,8.29662864423077,8.474954373076923,8.653280101923077,8.831605830769231,9.009931559615385,9.18825728846154,9.366583017307693,9.544908746153846,{"y":9.723234475,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.405,7.225614761538462,7.046229523076923,6.866844284615385,6.687459046153847,6.508073807692308,6.328688569230769,6.14930333076923,5.969918092307692,5.790532853846154,5.611147615384615,5.431762376923077,5.252377138461538,{"y":5.0729919,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.594,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.813,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.695,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.626,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.342,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.341,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.746,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.256,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.256,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.734,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.405,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€16.06

Average Price Target€9.72

Lowest Price Target€5.07

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alec Stranahan

Bank of America Securities

€5.94

Sell

-23.62%

Downside

Reiterated

02/13/26

Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX)

Geoff Meacham

Citi

€5.09

Sell

-34.53%

Downside

Reiterated

01/30/26

Citi Keeps Their Sell Rating on Novavax (NVAX)

Thomas Shrader

BTIG

€16.13

Buy

107.33%

Upside

Reiterated

01/20/26

Novavax: Pfizer Partnership Validates Matrix‑M Platform and Supports Upside in Capital‑Light Growth Strategy

Sean Lee CFA

H.C. Wainwright

€9.34

Buy

20.03%

Upside

Reiterated

01/20/26

Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating

Pete Stavropoulos

Cantor Fitzgerald

€15.28

Buy

96.42%

Upside

Reiterated

01/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Anupam Rama

J.P. Morgan

€5.94→€5.09

Sell

-34.53%

Downside

Reiterated

11/18/25

Novavax price target lowered to $6 from $7 at JPMorganNovavax price target lowered to $6 from $7 at JPMorgan

Mayank Mamtani

B. Riley Securities

€13.58

Buy

74.59%

Upside

Reiterated

11/11/25

Novavax price target lowered to $16 from $18 at B. RileyNovavax price target lowered to $16 from $18 at B. Riley

Steve Scala

TD Cowen

€6.79

Hold

-12.70%

Downside

Reiterated

08/07/25

TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alec Stranahan

Bank of America Securities

€5.94

Sell

-23.62%

Downside

Reiterated

02/13/26

Bank of America Securities Sticks to Their Sell Rating for Novavax (NVAX)

Geoff Meacham

Citi

€5.09

Sell

-34.53%

Downside

Reiterated

01/30/26

Citi Keeps Their Sell Rating on Novavax (NVAX)

Thomas Shrader

BTIG

€16.13

Buy

107.33%

Upside

Reiterated

01/20/26

Novavax: Pfizer Partnership Validates Matrix‑M Platform and Supports Upside in Capital‑Light Growth Strategy

Sean Lee CFA

H.C. Wainwright

€9.34

Buy

20.03%

Upside

Reiterated

01/20/26

Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating

Pete Stavropoulos

Cantor Fitzgerald

€15.28

Buy

96.42%

Upside

Reiterated

01/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Anupam Rama

J.P. Morgan

€5.94→€5.09

Sell

-34.53%

Downside

Reiterated

11/18/25

Novavax price target lowered to $6 from $7 at JPMorganNovavax price target lowered to $6 from $7 at JPMorgan

Mayank Mamtani

B. Riley Securities

€13.58

Buy

74.59%

Upside

Reiterated

11/11/25

Novavax price target lowered to $16 from $18 at B. RileyNovavax price target lowered to $16 from $18 at B. Riley

Steve Scala

TD Cowen

€6.79

Hold

-12.70%

Downside

Reiterated

08/07/25

TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novavax

3 Months

xxx

Success Rate

12/17 ratings generated profit

Average Return

+13.47%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.59% of your transactions generating a profit, with an average return of +13.47% per trade.

1 Year

Alec StranahanBank of America Securities

Success Rate

6/17 ratings generated profit

Average Return

+3.09%

a rating ―

Copying Alec Stranahan's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +3.09% per trade.

2 Years

xxx

Success Rate

6/17 ratings generated profit

Average Return

-2.12%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of -2.12% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVV1 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVV1 has received 3 Buy Ratings, 1 Hold Ratings, and 11 Sell Ratings. NVV1 average Analyst price target in the past 3 months is 9.72.

Each month's total comprises the sum of three months' worth of ratings.

NVV1 Financial Forecast

NVV1 Earnings Forecast

The previous quarter’s earnings for NVV1 were €0.09.

NVV1 Sales Forecast

The previous quarter’s earnings for NVV1 were €124.41M.

NVV1 Stock Forecast FAQ

What is DE:NVV1’s average 12-month price target, according to analysts?

Based on analyst ratings, Novavax’s 12-month average price target is 9.72.

What is DE:NVV1’s upside potential, based on the analysts’ average price target?

Novavax has 24.98% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novavax a Buy, Sell or Hold?

Novavax has a consensus rating of Hold, which is based on 3 buy ratings, 1 hold ratings and 2 sell ratings.

What is Novavax’s share price target?

The average share price target for Novavax is 9.72. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €16.06 ,and the lowest forecast is €5.07. The average share price target represents 24.98% Increase from the current price of €7.78.

What do analysts say about Novavax?

Novavax’s analyst rating consensus is a Hold. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Novavax?

To buy shares of DE:NVV1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novavax (NVV1) Stock Forecast & Price Target

NVV1 Analyst Ratings

NVV1 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novavax

NVV1 Analyst Recommendation Trends

NVV1 Financial Forecast

NVV1 Earnings Forecast

NVV1 Sales Forecast

NVV1 Stock Forecast FAQ

Detailed List of Analyst Forecasts